RGEN : Analysis & Opinions

  1. Positive Results on MDCO's Cangrelor - Analyst Blog

    January 10, 2013
    The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase III candidate, ...
  2. Optimer's Dificid Sales Look Good - Analyst Blog

    January 9, 2013
    Optimer Pharmaceuticals Inc. (OPTR) recently announced its preliminary sales for the fourth quarter and full year 2012. ...
  3. Abbott's ABSORB in Phase III Trial - Analyst Blog

    January 9, 2013
    Abbott Laboratories (ABT) recently announced that its Absorb Bioresorbable Vascular Scaffold (BVS) device has moved into ...
  4. Repligen, Pfizer Collaborate - Analyst Blog

    January 8, 2013
    Repligen Corporation (RGEN) recently joined forces with Pfizer, Inc. (PFE) for the advancement of its spinal muscular atrophy ...
  5. BioMimetic's Pipeline Progresses - Analyst Blog

    January 7, 2013
    Biotechnology company, BioMimetic Therapeutics, Inc. (BMTI) recently announced that it has started enrolling patients for ...
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center